ArticlePloS one2014
Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6/36 cells.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 62 citations in OpenAlex.
- Dissecting placental host-pathogen interactions: Rift Valley fever virus infection in early human trophoblast stem cells.iScience · 2026Article
- Article
- Review
- Ultracentrifugation Purification of Cache Valley Virus Using Iodixanol.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Cell line bias in virus research: implications for viral propagation and biological interpretation.Frontiers in cellular and infection microbiology · 2025Review
- Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice.Emerging microbes & infections · 2024Article
- CK1 and PP1 regulate Rift Valley fever virus genome replication through L protein phosphorylation.Antiviral research · 2024Article
- Article
- Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.NPJ vaccines · 2023Review
- A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques.NPJ vaccines · 2023Article
- An adenovirus-vectored RVF vaccine confers complete protection against lethal RVFV challenge in A129 mice.Frontiers in microbiology · 2023Article
- Review
- Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset.NPJ vaccines · 2022Article
- Vector and Host C-Type Lectin Receptor (CLR)-Fc Fusion Proteins as a Cross-Species Comparative Approach to Screen for CLR-Rift Valley Fever Virus Interactions.International journal of molecular sciences · 2022Article
- Article
- Rift Valley fever virus 78kDa envelope protein attenuates virus replication in macrophage-derived cell lines and viral virulence in mice.PLoS neglected tropical diseases · 2021Article
- Rift Valley fever virus detection in susceptible hosts with special emphasis in insects.Scientific reports · 2021Article
- Isolation and Identification of a Novel Phlebovirus, Hedi Virus, from Sandflies Collected in China.Viruses · 2021Article
- The Change P82L in the Rift Valley Fever Virus NSs Protein Confers Attenuation in Mice.Viruses · 2021Article
- Development of a Simian RNA Polymerase I Promoter-Driven Reverse Genetics for the Rescue of Recombinant Rift Valley Fever Virus from Vero Cells.Journal of virology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rift Valley fever virus (RVFV), genus Phlebovirus, family Bunyaviridae is a zoonotic arthropod-borne virus able to transition between distant host species, causing potentially severe disease in humans and ruminants. Viral proteins are encoded by three genomic segments, with the medium M segment coding for four proteins: nonstructural NSm protein, two glycoproteins Gn and Gc and large 78 kDa glycoprotein (LGp) of unknown function. Goat anti-RVFV polyclonal antibody and mouse monoclonal antibody, generated against a polypeptide unique to the LGp within the RVFV proteome, detected this protein in gradient purified RVFV ZH501 virions harvested from mosquito C6/36 cells but not in virions harvested from the mammalian Vero E6 cells. The incorporation of LGp into the mosquito cell line - matured virions was confirmed by immune-electron microscopy. The LGp was incorporated into the virions immediately during the first passage in C6/36 cells of Vero E6 derived virus. Our data indicate that LGp is a structural protein in C6/36 mosquito cell generated virions. The protein may aid the transmission from the mosquitoes to the ruminant host, with a possible role in replication of RVFV in the mosquito host. To our knowledge, this is a first report of different protein composition between virions formed in insect C6/36 versus mammalian Vero E6 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.